1. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling
- Author
-
Gottlieb, SL, Giersing, B, Boily, M-C, Chesson, H, Looker, KJ, Schiffer, J, Spicknall, I, Hutubessy, R, Broutet, N, and WHO HSV Vaccine Impact Modelling Meeting Working Group
- Subjects
0301 basic medicine ,viruses ,Herpesvirus 2, Human ,HSL and HSV ,Herpesvirus 1, Human ,Research & Experimental Medicine ,Herpes simplex virus ,medicine.disease_cause ,COST-EFFECTIVENESS ,0302 clinical medicine ,EPIDEMIOLOGY ,Medicine ,030212 general & internal medicine ,HIV ACQUISITION ,11 Medical and Health Sciences ,Reproductive health ,Hsv infection ,WOMEN ,Herpes Simplex Virus Vaccines ,GENITAL HERPES ,WHO HSV Vaccine Impact Modelling Meeting Working Group ,Infectious Diseases ,Medicine, Research & Experimental ,Dynamic models ,Molecular Medicine ,Life Sciences & Biomedicine ,medicine.medical_specialty ,TRANSMISSION ,Immunology ,World Health Organization ,Modelling ,World health ,TYPE-2 ,03 medical and health sciences ,07 Agricultural and Veterinary Sciences ,Virology ,Impact modelling ,Sexually transmitted infections ,Humans ,SEXUALLY-TRANSMITTED INFECTIONS ,Science & Technology ,Herpes Genitalis ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Public Health, Environmental and Occupational Health ,Herpes Simplex ,Expert consultation ,06 Biological Sciences ,ANTIVIRAL THERAPY ,PREVENTION ,030104 developmental biology ,Family medicine ,HSV vaccines ,business - Abstract
Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.
- Published
- 2016